Cardiology News: June 2021

DMS Cardiology News June, 2021 has information on heart failure, mortality rates, hypertension, coronary artery disease, evaluation & treatment, angina, irregular heartbeat, heart valve replacement, heart attack, and more.

All articles are published on reliable and respected sources cited with links to read the original full article. 

Should rare cases of heart inflammation put your COVID-19 vaccine plans on hold?

23 June, 2021 - Heart.org
EXCERPT:

A possible link between some COVID-19 vaccines and heart inflammation bears close monitoring, but it's no reason for parents or their teenage children to avoid vaccination.
That's what researchers are saying after several reports of the inflammation in teens and adults who had been vaccinated recently.

Such cases appear to be rare, said Dr. James de Lemos, a professor of medicine at UT Southwestern Medical Center in Dallas. "They don't change the overall dynamic," he said, and people should get vaccinated.

As of June 21, the Centers for Disease Control and Prevention and the Food and Drug Administration had confirmed 393 cases of myocarditis, inflammation of the heart muscle, or pericarditis, inflammation of the sac that surrounds the heart, in people 30 and younger who had received either the Pfizer or Moderna vaccines. That's out of more than 300 million doses administered in the U.S.

What can heart failure trialists learn from oncology trialists?

21 June, 2021 - Oxford Academic - European Heart Journal
Abstract
Globally, there has been little change in mortality rates from cardiovascular (CV) diseases or cancers over the past two decades (1997–2018). This is especially true for heart failure (HF) where 5-year mortality rates remain as high as 45–55%. In the same timeframe, the proportion of drug revenue, and regulatory drug approvals for cancer drugs, far out paces those for CV drugs. In 2018, while cancer drugs made 27% of Food and Drug Administration drug approvals, only 1% of drug approvals was for a CV drug, and over this entire 20 year span, only four drugs were approved for HF in the USA. Cardiovascular trialists need to reassess the design, execution, and purpose of CV clinical trials. In the area of oncology research, trials are much smaller, follow-up is shorter, and targeted therapies are common. Cardiovascular diseases and cancer are the two most common causes of death globally, and although they differ substantially, this review evaluates whether some elements of oncology research may be applicable in the CV arena. As one of the most underserved CV diseases, the review focuses on aspects of cancer research that may be applicable to HF research with the aim of streamlining the clinical trial process and decreasing the time and cost required to bring safe, effective, treatments to patients who need them. The paper is based on discussions among clinical trialists, industry representatives, regulatory authorities, and patients, which took place at the Cardiovascular Clinical Trialists Workshop in Washington, DC, on 8 December 2019 (https://www.globalcvctforum.com/2019 (14 September 2020)).

Percutaneous Retrieval of an Inferior Vena Cava Filter Penetrating Into the Duodenum

14 June, 2021 - JACC
EXCERPT:

Images in Intervention: Hiroyuki Gibo, Shota Saito, Jiro Koya, Yutaro Yasui, Yusuke Tokuda, Kazuya Sugitatsu, Yasuhiro Makita, Kazuharu Suzuki, Shuichi Miyamoto, and Morio Shoda

Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients

14 June, 2021 - AHA Journals
EXCERPT:

A possible link between some COVID-19 vaccines and heart inflammation bears close monitoring, but it's no reason for parents or their teenage children to avoid vaccination.
That's what researchers are saying after several reports of the inflammation in teens and adults who had been vaccinated recently.

Such cases appear to be rare, said Dr. James de Lemos, a professor of medicine at UT Southwestern Medical Center in Dallas. "They don't change the overall dynamic," he said, and people should get vaccinated.

As of June 21, the Centers for Disease Control and Prevention and the Food and Drug Administration had confirmed 393 cases of myocarditis, inflammation of the heart muscle, or pericarditis, inflammation of the sac that surrounds the heart, in people 30 and younger who had received either the Pfizer or Moderna vaccines. That's out of more than 300 million doses administered in the U.S.

Coronary Artery Disease Evaluation and Management Considerations for High Risk Occupations: Commercial Vehicle Drivers and Pilots

07 June, 2021 - AHA Journals
EXCERPT:

Optimal treatment of stable ischemic heart disease for those in the transportation industry is considered in the context of the individual’s health, as well as with the perspective that sudden impairment could have catastrophic consequences for others.

This article focuses on two high-risk occupations that one may encounter in practice: commercial motor vehicle drivers and commercial pilots. This article discusses coronary heart disease in patients in high-risk occupations and covers current guideline recommendations for screening, treatment, and secondary prevention.

The importance of the complementary perspectives of the regulatory agency, medical examiners, physicians, and pilot or driver are considered in this narrative review, as are considerations for future guideline updates.

Prioritizing Hypertension Control in Cardiology Practices

07 June, 2021 - ACC 
EXCERPT:
Uncontrolled hypertension may lead to heart and kidney disease and stroke and may increase vulnerability to COVID-19, according to an article published June 7 in the Journal of the American College of Cardiology. In the article, William J. Oetgen, MD, MBA, MACC, and Janet S. Wright, MD, FACC, urge the cardiology community to prioritize hypertension control on a national scale.

Do you have questions about a medical case or need help understanding treatment plans and options?

Health & Patient Advocacy | Medical Case Review

Medical Expert Witness

Dalawari Medical Services - Medical Consulting

Click here to Contact Us via email  or  Call + (804)-991-4109

About Jasdeep Dalawari MD

Experienced General and Specialist Physician with a demonstrated history of working in the medical practice industry. Skilled in Interventional, Endovascular, Vascular, and General Cardiovascular Medicine; Emergency Medicine; Healthcare Consulting, including Peer Review, Expert Witness, and Utilization Review; and Medical Education. Strong healthcare services professional with an MS focused in Health Administration from Virginia Commonwealth University.